HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quality King acquisition?

This article was originally published in The Rose Sheet

Executive Summary

Distributor of designer fragrances, hair, nail products enters confidentiality agreement with Parlux Fragrances to evaluate possible acquisition of prestige fragrance manufacturer and international distributor, Parlux announces Oct. 22. Confidentiality agreement will allow Ronkonkoma, N.Y.-based Quality King to conduct due diligence review of candidate, but company notes there is "no assurance that any transaction will result from such a review." Quality King distributes Benetton, smell THIS fragrances. Parlux fragrance portfolio includes Perry Ellis, Ocean Pacific and Jockey...

You may also be interested in...



Parlux acquisition talks end

Parlux Fragrances and Quality King abandon talks regarding the potential acquisition of Parlux, fragrance manufacturer says, noting "business combination with Quality King does not meet our strategic objectives at this time." Parlux entered into confidentiality agreement with Quality King to explore acquisition opportunities Oct. 22 (1"The Rose Sheet" Oct. 28, 2002, In Brief)...

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

UsernamePublicRestriction

Register

RS010711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel